| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.MOLONC.2015.02.011 |
| P8608 | Fatcat ID | release_3zfj4utd65gzrjuabbez5siami |
| P932 | PMC publication ID | 4516171 |
| P698 | PubMed publication ID | 25888066 |
| P5875 | ResearchGate publication ID | 273579622 |
| P2093 | author name string | Donald A Berry | |
| P2860 | cites work | I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 |
| Detecting an overall survival benefit that is derived from progression-free survival | Q34063143 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| The Innovative Medicines Initiative: an engine for regulatory science | Q34453618 | ||
| Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials | Q35041013 | ||
| Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials | Q35057399 | ||
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative | Q35680026 | ||
| Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. | Q36212421 | ||
| Bayesian clinical trials | Q36399554 | ||
| Adaptive clinical trials in oncology | Q37953783 | ||
| National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network | Q38214265 | ||
| The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research | Q38464684 | ||
| The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development | Q84132345 | ||
| Multicompany trials adapt to disciplines beyond cancer | Q87049794 | ||
| Large personalised medicine trial in lung cancer heralds new research partnership | Q87702513 | ||
| Trial watch: Lung cancer trial aims to bolster personalized medicine | Q87979213 | ||
| Neratinib Graduates to I-SPY 3 | Q88009562 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 951-959 | |
| P577 | publication date | 2015-03-11 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research | |
| P478 | volume | 9 |
| Q52676785 | A Bayesian basket trial design using a calibrated Bayesian hierarchical model. |
| Q39192426 | A response-adaptive design of initial therapy for emergency department patients with heart failure |
| Q97422216 | A review of big data and medical research |
| Q52371842 | Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. |
| Q37601709 | Adaptive Randomization of Neratinib in Early Breast Cancer |
| Q37601722 | Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer |
| Q46111530 | Advancing Clinical Trials to Streamline Drug Development |
| Q92137042 | An "all-wheel drive" proposal to accelerate clinical research in common and rare neurological diseases |
| Q89591831 | An overview of precision oncology basket and umbrella trials for clinicians |
| Q48162626 | Balanced covariates with response adaptive randomization |
| Q58804958 | Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway |
| Q36089590 | CNS Anticancer Drug Discovery and Development Conference White Paper. |
| Q92132872 | Challenges and approaches to implementing master/basket trials in oncology |
| Q38905607 | Clinical Trials in the Genomic Era. |
| Q99545825 | Clinical trial design: Past, present, and future in the context of big data and precision medicine |
| Q36534713 | Clinical trial designs incorporating predictive biomarkers. |
| Q48341652 | Commentary to "Patients not patents: drug research and development as a public enterprise". |
| Q47322951 | Definitions and statistical properties of master protocols for personalized medicine in oncology |
| Q92594629 | Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data |
| Q89693629 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial |
| Q38904226 | Efficiencies of platform clinical trials: A vision of the future |
| Q38631473 | Emerging innovations in clinical trial design |
| Q45059047 | Innovations in Clinical Trial Design in the Era of Molecular Profiling |
| Q38639549 | Is the NCI MATCH trial a match for gynecologic oncology? |
| Q89592800 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial |
| Q57124868 | Master protocol trials in oncology: Review and new trial designs |
| Q37481946 | PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms |
| Q50355746 | Precision oncology: A new era of cancer clinical trials |
| Q47737073 | Precision oncology: neither a silver bullet nor a dream |
| Q92112381 | Reporting of master protocols towards a standardized approach: A systematic review |
| Q55179580 | Signature program: a platform of basket trials. |
| Q39126105 | Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples |
| Q50498479 | Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. |
| Q38691922 | The role of adaptive trial designs in drug development |
| Q39965206 | What's in a Name? A Coordinated Approach toward the Correct Use of a Uniform Nomenclature to Improve Patient Reports and Databases |
Search more.